Fate Therapeutics Stock Debt To Equity
| FATE Stock | USD 3.95 0.09 2.23% |
Fate Therapeutics fundamentals help investors to digest information that contributes to Fate Therapeutics' financial success or failures. It also enables traders to predict the movement of Fate Stock. The fundamental analysis module provides a way to measure Fate Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fate Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.28 | 0.16 |
Fate | Debt To Equity |
Fate Therapeutics Company Debt To Equity Analysis
Fate Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Fate Therapeutics Debt To Equity | 0.19 % |
Most of Fate Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fate Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Fate Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Fate Therapeutics is extremely important. It helps to project a fair market value of Fate Stock properly, considering its historical fundamentals such as Debt To Equity. Since Fate Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fate Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fate Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Fate Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Fate Therapeutics has a Debt To Equity of 0.193%. This is 99.64% lower than that of the Biotechnology sector and 99.0% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.6% higher than that of the company.
Fate Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fate Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fate Therapeutics could also be used in its relative valuation, which is a method of valuing Fate Therapeutics by comparing valuation metrics of similar companies.Fate Therapeutics is currently under evaluation in debt to equity category among related companies.
Fate Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Fate Therapeutics from analyzing Fate Therapeutics' financial statements. These drivers represent accounts that assess Fate Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Fate Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 7.5B | 5.5B | 977.0M | 368.1M | 349.7M | |
| Enterprise Value | 1.3B | 7.4B | 5.5B | 1.0B | 429.7M | 408.2M |
Fate Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (20.99) % | ||||
| Current Valuation | 189.28 M | ||||
| Shares Outstanding | 113.78 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 93.91 % | ||||
| Number Of Shares Shorted | 18.92 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 10.33 X | ||||
| Revenue | 63.53 M | ||||
| Gross Profit | (224.15 M) | ||||
| EBITDA | (159.33 M) | ||||
| Net Income | (160.93 M) | ||||
| Cash And Equivalents | 568.85 M | ||||
| Cash Per Share | 5.86 X | ||||
| Total Debt | 103.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 6.55 X | ||||
| Book Value Per Share | 3.73 X | ||||
| Cash Flow From Operations | (132.26 M) | ||||
| Short Ratio | 7.34 X | ||||
| Earnings Per Share | (1.64) X | ||||
| Target Price | 7.8 | ||||
| Number Of Employees | 181 | ||||
| Beta | 1.68 | ||||
| Market Capitalization | 459.68 M | ||||
| Total Asset | 506.22 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 292.45 M | ||||
| Current Asset | 47.4 M | ||||
| Current Liabilities | 14.68 M | ||||
| Net Asset | 506.22 M |
About Fate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fate Therapeutics Piotroski F Score and Fate Therapeutics Altman Z Score analysis. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.